Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia (NCT06982820)
A Prospective, Randomized, Double-blind, Controlled Study to Produce Guidelines for Integrating Prism for MDD Therapy (Reward System [RS] Upregulation) and to Demonstrate Its Superiority Over Sham Therapy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroencephalography (EEG).
Who can join: Review the eligibility criteria below.
Location: Butler Hospital — Providence, Rhode Island
Age range: 22 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Butler Hospital — Providence, Rhode Island
- Houston Center For Advanced Psychiatric Treatment — Houston, Texas
- Sheba Medical Center — Ramat Gan,
📞 Contact the Study Coordinator
Phone: +972-54-2347770
Email: adar@graymatters-health.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Depressive Disorder, Major
- Psilocybin for Major Depressive Disorder (MDD) — Birmingham, Alabama
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder — Birmingham, Alabama
- Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Boston, Massachusetts
- bWell-D Pilot Randomized Controlled Trial — Vancouver, British Columbia
- Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Belmont, Massachusetts
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — Birmingham, Alabama
Explore by condition: All Depressive Disorder, Major clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.